电邮这篇文章 Bendamustin v terapii nekhodzhkinskikh limfom
- 作者: Semenova AA1
-
隶属关系:
- 期: 卷 14, 编号 2 (2012)
- 页面: 10-12
- 栏目: Articles
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.06.2012
- URL: https://modernonco.orscience.ru/1815-1434/article/view/29479
- ID: 29479
如何引用文章
全文:
详细
参考
- United States Food and Drug Administration. Approval letter NDA 22-249. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022249s000ltr.pdf
- United States Food and Drug Administration. Approval letter NDA 22-303. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022303s000ltr.pdf
- Anger G, Hesse P, Baufield H. Treatment of multiple myeloma with a new cytostatic agent: g-1-methyl-5-bis-(b-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride. Dtsch Med Wochenschr 1969; 94: 2495-500.
- Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-17.
补充文件
